Dee Datta, Ph.D., has been appointed chief business officer, XOMA Corp., and Danny Hart has been named vice president, General Counsel. Dr. Datta and Mr. Hart will report to XOMA’s chief executive officer, Jim Neal.

Dr. Datta brings extensive leadership experience in business development, alternative financing strategies and corporate strategy. Dr. Datta previously served as vice president of corporate development at Forty Seven, Inc., where she managed business development, strategy and transactions, company financing and investor relations. Most recently, Dr. Datta was senior director of business development at XOMA.

Mr. Hart brings experience in corporate governance, securities law compliance, and mergers and acquisitions. Prior to joining XOMA, Mr. Hart was vice president, business development at PDL BioPharma, Inc., where he focused on the company’s investment activity by identifying, evaluating, structuring and completing alternative, non-dilutive financing investments for late-stage pharmaceutical, device and diagnostic companies. Mr. Hart also served in various legal capacities at PDL, where he led PDL’s transactional efforts, completing over $1 billion in investment transactions during his tenure. Previously, Mr. Hart was an associate with Hogan & Hartson LLP, where his practice focused on securities, corporate governance and M&As.

“Dee and Danny bring significant value to XOMA’s team as we continue to execute on our transformation into a royalty aggregator,” said Mr. Neal. “Their expertise and experience will be invaluable as we expand our portfolio to drive revenue growth and create value for shareholders. We are excited they have chosen to join our team.”